招商通知 第三届全球手术机器人大会 第二届全球医疗科技大会 2025年7月1日， 美敦力（Medtronic） 宣布了一项人事任命。现任 碧迪医疗（BD）高级副总裁、总法律顾问 Michelle Quinn（米歇尔·奎因） ，接替即将退休的 Ivan Fong ，出任美敦力高级副总裁、总法律顾问兼公司 秘书。该任命将于2025年7月21日正式生效。 此项任命，正值美敦力深处战略转型的重要阶段。随着全球医疗器械行业面临日益复杂的监管环境与创新竞 争，美敦力此举被视为在法律与合规领域的一次关键布局。 # I v a n F o n g ： 前 任 背 景 与离任 她毕业于科尔盖特大学，获得政治学学士学位，随后取得维拉诺瓦大学法学博士（Juris Doctor）学位，为其职 业生涯奠定了坚实的法律基础。 曾任 3M 首席法律与政策官 曾任美国国土安全部总法律顾问 曾任 Cardinal Health 首席法律官 此次人事更迭，也标志着 Ivan Fong 在美敦力的阶段性告别。 Ivan Fong 自 2022 年加入美敦力以来，一直担任高级副总裁、总法律顾问兼公司秘书，领导美敦力全球法律事 务。他的职业履历同样卓 ...

朋友們大家好，大家早上中午晚上好，這裡是提阿非羅 現在是2025年7月2日華爾街午盤時間 我們來更新比特幣的行情 這個是比特幣的日線圖 從日線級別來看 我們發現比特幣今天果然出現了 一根非常大的陽線 那麼過去這兩天下跌 我們可以看到成交量並不是特別的多 那麼在下跌的時候 很多人認為我是不是錯失了最高點 那麼這個地方是不是要馬上開啟熊市了 實際上這是一種過分的擔憂 我們可以看到之前在這一帶盤整的時候 成交量都是比較的小 可以說是一個縮量的回調 那麼在一個下跌 然後把前面的低點出現跌破收回 而且有巨量的k線 然後來到這邊進行一段時間的縮量回調 那有什麼問題呢 我個人是覺得這還算是比較的正常 然後我們可以看到 今天這個日線 好像成交量終於上來了 那麼也就是說這樣的一次放量的反彈 來到這邊縮量的盤整 然後緊接著成交量又出來了 又再繼續往上漲 我覺得來到更高的位置是很可以期待的 但是目前來說我們可以看到 這邊有一個下降趨勢線 好像要嘗試突破 我希望說今天的日線能夠收在這個上面 然後吸引更更多人在邊去做多 然後來測試前面的高點 來測試前面這一帶的高點 實際上在這邊盤整的時候 我一直都有一個更高的預期 那麼在漫長的盤整過程 ...

Summary of Outlook Therapeutics Conference Call Company Overview - **Company**: Outlook Therapeutics - **Ticker**: OTLK (trades on Nasdaq) [4] Recent Achievements - **Product**: Lightnova - **Regulatory Approvals**: Lightnova approved in the EU and UK; received positive recommendation from NICE for use in the UK [5][6] - **Launch**: Launched simultaneously in Germany and the UK in May 2025; first patients dosed in both countries [6] Market Landscape - **Industry**: Treatment of wet Age-related Macular Degeneration (AMD) - **Market Size**: The European market for wet AMD treatments is valued at approximately $3.6 billion annually, with 8 million anti-VEGF injections per year [9] - **Injection Distribution**: Germany accounts for 1.7 million injections, while the UK accounts for 1.3 million [10] Competitive Positioning - **Market Share**: Off-label bevacizumab holds a 33% market share in Europe, with Germany at 50% and the UK at 5% [11][12] - **Cost-Effectiveness**: Lightnova positioned as a cost-effective first-line treatment option for wet AMD [9][12] Pricing Strategy - **UK Pricing**: List price set at £470, the lowest among approved products; patient access scheme in place for competitive net pricing [16][18] - **Germany Pricing**: List price set at €751.61; negotiations for a post-launch price expected in early 2026 [20][19] Commercial Launch Strategy - **Market Access**: Focus on subnational access critical for success; rebate agreements in place covering 50% of the population in Germany, expected to increase to 90% by year-end [26] - **Team Experience**: Strong teams with extensive ophthalmology experience in both Germany and the UK [24] Physician Engagement - **Receptiveness**: Positive feedback from ophthalmologists regarding Lightnova; significant interest in an ophthalmic standard formulation of bevacizumab [13][14] - **Educational Efforts**: Focus on educating physicians about the ophthalmic formulation and clinical data supporting Lightnova [35][36] Future Expansion Plans - **Market Expansion**: Approved in 31 countries; focus on launching in Italy, Spain, France, Ireland, and the Nordics [44][47] - **Potential Partnerships**: Currently focused on maximizing Lightnova's potential independently, but open to partnerships if beneficial [48] FDA Approval Update - **BLA Submission**: BLA submitted to the FDA in February 2025; PDUFA goal date set for August 27, 2025 [50][51] - **Expectations**: Confident in the data provided to the FDA supporting approval for wet AMD treatment [75][76] Financial Outlook - **Liquidity**: Recent capital raised through a CMPO; sufficient funds to support operations through the PDUFA decision [58] - **Profit Margins**: Anticipated healthy profit margins, with a focus on minimizing dilution during financing [63] Conclusion - **Key Milestones**: Upcoming quarterly results expected in August, along with the FDA decision; preparations for further European launches ongoing [84][85]

朋友們 2025年6月24日華爾街午盤時間 我們來更新比特幣的行情 這個是比特幣的日線圖 從日線級別來看 我們發現比特幣之前在前面的低點下方 跌下來確實就是一個空頭的陷阱 那麼如果說它重新又收了回去 而且我是覺得 最好是收一根小小的看漲吞沒我就滿足了 也就是說如果收回去 是這樣子的一根大陽線 我覺得就可以了 結果它收了那麼大一根陽線 你會說這個地方有什麼頹勢嗎 我是沒有看到 你可以看到過去這一個禮拜 從這裡開始這裡開始這裡開始都在往下跌 醞釀情緒做空 然後一根收上去 在這過去這一禮拜 如果說沒有止盈的空頭 那麼現在都在水下了 那麼表明著說還有充分的燃料對不對 那麼這樣子的話我們就會認為 比特幣目前還算是不錯的 而且你如果說看我在行情中 經常畫出這種紅色的這種圈圈是什麼意思 是一個假突破或者說假跌破 然後延伸一下可能是一個AMD的形態 我先把這個大的AMD給大家拿出來看一看 就是複盤一下 原先的時候我在這邊畫了一個AMD 這在哪裡你可以看到這是很久以前畫的 我會認為這邊是盤整 然後是假跌破 然後來到上方做投遞 這是一個很完美的AMD是不是 那是周線級別 現在我們切換到日線級別 我們也畫一個新的AMD出來 這樣一 ...

Core Insights - The article provides an analysis of a specific company, focusing on its financial performance and market position, but does not offer exhaustive details or personalized investment advice [2][3] Financial Performance - The company has shown significant growth in revenue, with a reported increase of 15% year-over-year, reaching $1.5 billion in the latest quarter [2] - Operating income has also improved, with a margin expansion of 3 percentage points, indicating better cost management and operational efficiency [2] Market Position - The company has strengthened its market share, now holding 25% of the market, up from 22% in the previous year, reflecting successful strategic initiatives [2] - Competitive analysis suggests that the company is well-positioned against its main rivals, benefiting from unique product offerings and strong brand loyalty [2] Future Outlook - Analysts project continued growth, with expectations of a 10% increase in revenue for the next fiscal year, driven by new product launches and expansion into emerging markets [2] - The company is investing heavily in research and development, allocating $200 million to innovate and enhance its product line, which is anticipated to yield positive results in the long term [2]

撰文丨王聪 编辑丨王多鱼 排版丨水成文 司美格鲁肽 是一种胰高血糖素样肽-1 受体 （ GLP-1 ） 激动剂，它彻底改变了 2 型糖尿病的治疗方式， 近年来还被广泛用于治疗肥胖症，成为减肥和降低心血管疾病风险的良方。 然而，此前在糖尿病临床试验中发现，GLP-1 受体激动剂可能与糖尿病患者视网膜病变并发症有关，但也 有研究显示相反的结论——其具有神经保护或血管益处。因此，长期使用 GLP-1 激动剂是否会增加 糖尿 病患者患 新生血管性年龄相关性黄斑变性 （nAMD） 的风险，目前仍无定论。 年龄相关性黄斑变性 （AMD） 导致的失明病例比其他任何视网膜疾病都要多。其中，新生血管性年龄相关 性黄斑变性 （ nAMD ） 虽然不如干性年龄相关性黄斑变性 （dAMD） 常见，但几乎所有的突发性、 不 可逆的中心视力丧失都是由 nAMD 引起的，其原因是异常血管生长损害了关键视力区视网膜黄斑。 近日，多伦多大学的研究人员在 《美国医学会杂志》子刊 JAMA Ophthalmology 上发表了题为： Glucagon-Like Peptide-1 Receptor Agonists and Risk of Neo ...

SAN DIEGO, June 12, 2025 (GLOBE NEWSWIRE) -- Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a technology company in Defense, National Security and Global Markets, today announced its participation in NATO’s At-Sea Demonstration (ASD)/Formidable Shield (FS) 25. This extensive live-fire exercise, the largest of its kind in the European theater, is hosted biennially by the U.S. 6th Fleet and executed by Naval Striking and Support Forces NATO. This year’s exercise comprised a series of live-fire even ...

SAN DIEGO, June 12, 2025 (GLOBE NEWSWIRE) -- Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a technology company in Defense, National Security and Global Markets, today announced its participation in NATO’s At-Sea Demonstration (ASD)/Formidable Shield (FS) 25. This extensive live-fire exercise, the largest of its kind in the European theater, is hosted biennially by the U.S. 6th Fleet and executed by Naval Striking and Support Forces NATO. This year’s exercise comprised a series of live-fire even ...

朋友們大家好，大家早上中午晚上好 這裡是提阿非羅 現在是2025年6月10日 華爾街午盤時間 我們來更新比特幣的行情 這個是比特幣的日線圖 從日線級別來看我們發現昨天的日線 真的是非常強勢的一根日線 然後收線在什麼位置呢 我們可以看到 它是收線在前面這個高點附近 然後就有那麼一點點的回調 那麼從日線級別來講 你可以看到昨天的成交量 還算是可以，超出了最近的平均值 那麼接下來如果說它有一個下跌 從日線級別來講 我是覺得它有可能 會把這一帶漲的比較快的空缺 給它補足一下 然後來測試前面這麼多的 小小的這種上影線 因為這一帶我會認為它有比較強的支撐 那麼如果說往下面跌 我就會認為它是一個 上漲a浪之後的下跌b浪 然後找到支撐再繼續往上漲 尤其是你可以看到這個高點 剛好是重疊之前這一帶的高點 那麼目前來說是不是有一個平行的頂部呢 而且這個平行的頂部是在之前的ALL TIME HIGH的下面 那麼這樣的一種情況 有時候會走成這個樣子 我現在姑且這麼畫一下 未必它會真的走成這個樣子 你可以看到它有可能在這邊 你可以看到好像平行的高點對不對 然後有可能是這樣子這樣子這樣子 如果說我看到 它出現這種蓄勢待發的感覺 而且到時候 ...

Core Viewpoint - Outlook Therapeutics has launched LYTENAVA™ (bevacizumab gamma) for the treatment of wet age-related macular degeneration (wet AMD) in Germany and the UK, marking a significant milestone as it is the first and only authorized ophthalmic formulation of bevacizumab for this condition in the European Union and UK [1][5][9] Company Overview - Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing ONS-5010/LYTENAVA™ to enhance the standard of care for retinal diseases [8] - The company has received centralized Marketing Authorization from the European Commission and the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK for LYTENAVA™ [5][8] Product Launch and Market Strategy - The commercial launch of LYTENAVA™ in Germany and the UK is supported by a strategic collaboration with Cencora to facilitate market access and distribution [4] - The company aims to ensure success in these markets and is preparing for additional launches across Europe later in 2025 and throughout 2026 [2] Market Context - Off-label repackaged bevacizumab is widely used in Europe and the US, with approximately 2.8 million injections annually in Europe and 2.7 million in the US for retinal diseases [3] - LYTENAVA™ has the potential to mitigate risks associated with the current off-label use of repackaged bevacizumab [3] Regulatory Status - In the United States, ONS-5010/LYTENAVA™ is currently investigational, and a Biologics License Application (BLA) has been resubmitted to the FDA [6][8] - In certain EU member states, ONS-5010/LYTENAVA™ must receive pricing and reimbursement approval before it can be sold [6]